Jack O’Meara

CEO at Aerska

Speaker

Growing up, I watched loved ones suffer through the long, anxious decline of Alzheimer’s disease. That experience stayed with me, and I’m committed to finding new ways to change this story. At Aerska, we’re working to combine brain shuttles with advanced genetic medicines to bring new hope to patients and families facing the many devastating diseases of the brain.

Prior to founding Aerska, Jack co-founded and served as CEO of Ochre Bio, where he raised $45M from top-tier VCs and secured over $70M in pharma partnering revenue, with more than $1B in potential milestones, while advancing a pipeline of RNAi medicines for advanced liver diseases. He began his career in management consulting, where he supported the global launch of Zolgensma at AveXis (now Novartis Gene Therapies). Jack holds technical degrees from the University of Galway, Ireland, and the University of Notre Dame, USA. His work has been featured in The Wall Street Journal, the Financial Times, and he was previously named a Forbes 30 Under 30 honoree in healthcare.